UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

Clinical pharmacology and therapeutics, 2008-02, Vol.83 (2), p.293-299

2008

Volltextzugriff (PDF)

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

Clinical pharmacology and therapeutics, 2009-08, Vol.86 (2), p.175-182

2009

Volltextzugriff (PDF)

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Clinical pharmacology and therapeutics, 2008-12, Vol.84 (6), p.679-683

2008

Volltextzugriff (PDF)

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

Clinical pharmacology and therapeutics, 2002-07, Vol.72 (1), p.50-61

2002

Volltextzugriff (PDF)

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

Clinical pharmacology and therapeutics, 2008-10, Vol.84 (4), p.475-480

2008

Volltextzugriff (PDF)

Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

Clinical pharmacology and therapeutics, 2007-06, Vol.81 (6), p.849-857

2007

Volltextzugriff (PDF)

Effect of L-000845704, an αVβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women

The journal of clinical endocrinology and metabolism, 2005-04, Vol.90 (4), p.2022-2028

2005

Volltextzugriff (PDF)

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

Clinical pharmacology and therapeutics, 2009-12, Vol.86 (6), p.659-666

2009

Volltextzugriff (PDF)

Acute Alertness-Promoting Effects of a Novel Histamine Subtype-3 Receptor Inverse Agonist in Healthy Sleep-Deprived Male Volunteers

Clinical pharmacology and therapeutics, 2010-12, Vol.88 (6), p.831-839

2010

Volltextzugriff (PDF)

Results of a randomized, dose‐ranging trial of etoricoxib in patients with osteoarthritis

British journal of rheumatology, 2002-09, Vol.41 (9), p.1052-1061

2002

Volltextzugriff (PDF)

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

The Lancet (British edition), 2008-11, Vol.372 (9653), p.1881-1893

2008

Volltextzugriff (PDF)

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

Journal of clinical pharmacology, 2008-06, Vol.48 (6), p.726-733

2008

Volltextzugriff (PDF)

The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers

European journal of clinical pharmacology, 2007-02, Vol.63 (2), p.135-141

2007

Volltextzugriff (PDF)

The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol

Journal of psychopharmacology (Oxford), 2012-02, Vol.26 (2), p.292-302

2012

Volltextzugriff (PDF)

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol

Journal of psychopharmacology (Oxford), 2012-02, Vol.26 (2), p.282-291

2012

Volltextzugriff (PDF)

Dose Proportionality of Oral Etoricoxib, a Highly Selective Cyclooxygenase-2 Inhibitor, in Healthy Volunteers

Journal of clinical pharmacology, 2001-10, Vol.41 (10), p.1106-1110

2001

Volltextzugriff (PDF)

Transplanted infections: donor-to-host transmission with the allograft

Annals of internal medicine, 1989-06, Vol.110 (12), p.1001

Gottesdiener, K M

1989

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

Clinical pharmacology and therapeutics, 2008-06, Vol.83 (6), p.840-847

2008

Volltextzugriff (PDF)

Individual and Combined Effects of Peroxisome Proliferator-Activated Receptor α and γ Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers

Journal of clinical pharmacology, 2005-05, Vol.45 (5), p.504-513

2005

Volltextzugriff (PDF)

Antagonism of the prostaglandin D 2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

Proceedings of the National Academy of Sciences - PNAS, 2006-04, Vol.103 (17), p.6682-6687

2006

Volltextzugriff (PDF)

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

Clinical infectious diseases, 2008-07, Vol.47 (1), p.137-140

2008

Volltextzugriff (PDF)

Effects of lorazepam on fear-potentiated startle responses in man

Journal of psychopharmacology (Oxford), 2005-05, Vol.19 (3), p.249-258

2005

Volltextzugriff (PDF)

Trypanosoma brucei brucei:Characterization of an ODC Null Bloodstream Form Mutant and the Action of Alpha-difluoromethylornithine

Experimental parasitology, 1998-03, Vol.88 (3), p.255-257

1998

Volltextzugriff (PDF)

Aprepitant has little inductive effect on CYP3A4 activity when coadministered with dexamethasone

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P73-P73

2005

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Clinical pharmacology and therapeutics, 2005-12, Vol.78 (6), p.675-688

2005

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(135)

Sprache

Englisch
(135)

Erscheinungsjahr

n.n

Thema

Science & Technology
(77)
Life Sciences & Biomedicine
(74)
Humans
(69)
Male
(57)
Biological And Medical Sciences
(51)
Adult
(49)
Female
(45)
Medical Sciences
(38)
Middle Aged
(36)
Pharmacology & Pharmacy
(36)
Pharmacology. Drug Treatments
(34)
Double-Blind Method
(32)
Cross-Over Studies
(27)
Animals
(23)
Adolescent
(22)
Area Under Curve
(17)
Dose-Response Relationship, Drug
(17)
Fundamental And Applied Biological Sciences. Psychology
(15)
Biochemistry & Molecular Biology
(14)
Trypanosoma Brucei
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

Effect of L-000845704, an αVβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

Acute Alertness-Promoting Effects of a Novel Histamine Subtype-3 Receptor Inverse Agonist in Healthy Sleep-Deprived Male Volunteers

Results of a randomized, dose‐ranging trial of etoricoxib in patients with osteoarthritis

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers

The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol

Dose Proportionality of Oral Etoricoxib, a Highly Selective Cyclooxygenase-2 Inhibitor, in Healthy Volunteers

Transplanted infections: donor-to-host transmission with the allograft

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

Individual and Combined Effects of Peroxisome Proliferator-Activated Receptor α and γ Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers

Antagonism of the prostaglandin D 2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

Effects of lorazepam on fear-potentiated startle responses in man

Trypanosoma brucei brucei:Characterization of an ODC Null Bloodstream Form Mutant and the Action of Alpha-difluoromethylornithine

Aprepitant has little inductive effect on CYP3A4 activity when coadministered with dexamethasone

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Suchergebnisse filtern